Logo image of HSDT

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Stock Overview

NASDAQ:HSDT - US42328V8019 - Common Stock

6.12 USD
-0.09 (-1.53%)
Last: 8/29/2025, 8:00:01 PM
5.98 USD
-0.14 (-2.29%)
After Hours: 8/29/2025, 8:00:01 PM

HSDT Key Statistics, Chart & Performance

Key Statistics
52 Week High1200
52 Week Low5.37
Market Cap6.61M
Shares1.08M
Float1.07M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1242.08
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/amc
IPO06-27 2014-06-27
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


HSDT short term performance overview.The bars show the price performance of HSDT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

HSDT long term performance overview.The bars show the price performance of HSDT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of HSDT is 6.12 USD. In the past month the price increased by 0.33%. In the past year, price decreased by -98.93%.

HELIUS MEDICAL TECHNOLOGIE-A / HSDT Daily stock chart

HSDT Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.07 230.89B
ISRG INTUITIVE SURGICAL INC 58.79 169.67B
BSX BOSTON SCIENTIFIC CORP 37.28 156.32B
SYK STRYKER CORP 30.46 149.64B
MDT MEDTRONIC PLC 16.78 119.05B
BDX BECTON DICKINSON AND CO 13.52 55.31B
IDXX IDEXX LABORATORIES INC 53.88 51.77B
EW EDWARDS LIFESCIENCES CORP 31.65 47.75B
RMD RESMED INC 28.74 40.19B
GEHC GE HEALTHCARE TECHNOLOGY 15.82 33.66B
DXCM DEXCOM INC 44.32 29.55B
PHG KONINKLIJKE PHILIPS NVR- NY 16.42 26.56B

About HSDT

Company Profile

HSDT logo image Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania and currently employs 21 full-time employees. The company went IPO on 2014-06-27. The firm is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.

Company Info

HELIUS MEDICAL TECHNOLOGIE-A

642 Newtown Yardley Road

Newtown PENNSYLVANIA 18940 US

CEO: Dane C. Andreeff

Employees: 21

HSDT Company Website

HSDT Investor Relations

Phone: 12159446100

HELIUS MEDICAL TECHNOLOGIE-A / HSDT FAQ

What is the stock price of HELIUS MEDICAL TECHNOLOGIE-A today?

The current stock price of HSDT is 6.12 USD. The price decreased by -1.53% in the last trading session.


What is the ticker symbol for HELIUS MEDICAL TECHNOLOGIE-A stock?

The exchange symbol of HELIUS MEDICAL TECHNOLOGIE-A is HSDT and it is listed on the Nasdaq exchange.


On which exchange is HSDT stock listed?

HSDT stock is listed on the Nasdaq exchange.


What is HELIUS MEDICAL TECHNOLOGIE-A worth?

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) has a market capitalization of 6.61M USD. This makes HSDT a Nano Cap stock.


How many employees does HELIUS MEDICAL TECHNOLOGIE-A have?

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) currently has 21 employees.


What are the support and resistance levels for HELIUS MEDICAL TECHNOLOGIE-A (HSDT) stock?

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) has a resistance level at 6.39. Check the full technical report for a detailed analysis of HSDT support and resistance levels.


Is HELIUS MEDICAL TECHNOLOGIE-A (HSDT) expected to grow?

The Revenue of HELIUS MEDICAL TECHNOLOGIE-A (HSDT) is expected to decline by -20.09% in the next year. Check the estimates tab for more information on the HSDT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy HELIUS MEDICAL TECHNOLOGIE-A (HSDT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HELIUS MEDICAL TECHNOLOGIE-A (HSDT) stock pay dividends?

HSDT does not pay a dividend.


When does HELIUS MEDICAL TECHNOLOGIE-A (HSDT) report earnings?

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) will report earnings on 2025-11-10, after the market close.


What is the Price/Earnings (PE) ratio of HELIUS MEDICAL TECHNOLOGIE-A (HSDT)?

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1242.08).


HSDT Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to HSDT. When comparing the yearly performance of all stocks, HSDT is a bad performer in the overall market: 99.96% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

HSDT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HSDT. While HSDT seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HSDT Financial Highlights

Over the last trailing twelve months HSDT reported a non-GAAP Earnings per Share(EPS) of -1242.08. The EPS decreased by -675.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -374.97%
ROE -1020.62%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-730.52%
Sales Q2Q%-76.37%
EPS 1Y (TTM)-675.33%
Revenue 1Y (TTM)-19.25%

HSDT Forecast & Estimates

For the next year, analysts expect an EPS growth of 69.06% and a revenue growth -20.09% for HSDT


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y69.06%
Revenue Next Year-20.09%

HSDT Ownership

Ownership
Inst Owners0.72%
Ins Owners0%
Short Float %N/A
Short Ratio0.01